JNCI Journal of the National Cancer Institute · 2013 · 61 citations · 18 references
MedicineOncologySurgeryChemotherapyGastrointestinal OncologyMolecular OncologyAdjuvant ChemotherapyAdjuvant TherapyCancer Survival AnalysisColorectal CancerMalignant NeoplasmsMolecular Tumor ProfilingColon Cancer Adjuvant TherapyColorectal Cancer Adjuvant TherapyColorectal Cancer PrognosisCox RegressionMismatch Repair DefectsOxaliplatin-based TherapyPost Hoc AnalysisSurvival Benefit Assessment
National Surgical Adjuvant Breast and Bowel Project protocol C-08 tested the worth of adding 1 year of bevacizumab to oxaliplatin-based standard adjuvant chemotherapy regimen in the treatment of stage II/III colon cancer. Although the overall result was negative, the possibility that a molecularly defined subset could benefit from bevacizumab cannot be ruled out. We performed post hoc Cox regression analyses to test for marker-by-treatment interactions for standard pathological features and survival analyses using the Kaplan-Meier method. All statistical tests were two-sided and considered statistically significant at the .05 level. Patients diagnosed with mismatch repair defective (dMMR) tumors derived statistically significant survival benefit from the addition of bevacizumab (hazard ratio [HR] = 0.52; 95% confidence interval [CI] = 0.29 to 0.94; P = .02) in contrast with no benefit in patients diagnosed with mismatch repair proficient tumors (HR = 1.03; 95% CI = 0.84 to 1.27; p = .78; P(interaction)= .04). Although a post hoc finding, this data suggests that a molecularly defined subset of colon cancer patients may derive clinical benefit from antiangiogenesis agents and underscores the need for independent validation in other clinical trials.
18
Comprehensive molecular characterization of human colon and rectal cancer
Fairooz F. Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2002 · 1.7K citations
Medicine, Oncology, Pharmacotherapy +13